IL27 and autoimmune gastritis: When IL-27 was injected into TxA23xEbi3−/− mice, stomachs were much healthier, evidenced by the reduction in the extent of atrophy, mucinous hyperplasia/metaplasia, and inflammatory infiltrate, and there were lower scores for inflammation, atrophy, and mucinous hyperplasia/metaplasia, demonstrating that IL-27 is able to inhibit autoimmune gastritis (224).